A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5 mcg, compared with two inhalations of Seretide 25/250 mcg, two inhalations of Ventoline 100 mcg, and placebo, delivered by pressurised metered dose inhalers, in patients with chronic obstructive pulmonary disease (COPD).
Study identifier:D5899C0748
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5 mcg, compared with two inhalations of Seretide 25/250 mcg, two inhalations of Ventoline 100 mcg, and placebo, delivered by pressurised metered dose inhalers, in patients with chronic obstructive pulmonary disease (COPD).
Medical condition
asthma
Phase
N/A
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
